Publications by authors named "S Cheeti"
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for -Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
J Clin Oncol
November 2024
Article Synopsis
- The study aimed to assess the safety, tolerability, and effectiveness of inavolisib combined with palbociclib and endocrine therapy for patients with specific types of breast cancer.
- A total of 53 patients participated, experiencing some treatment-related side effects, with common issues being stomatitis, hyperglycemia, and diarrhea, but overall the treatment was manageable.
- Results showed promising preliminary antitumor activity, with objective response rates of about 52% and 40%, and median progression-free survival of 23.3 and 35.0 months for different treatment combinations.
Dynamic in vitro absorption systems and mechanistic absorption modeling via PBPK have both shown promise in predicting human oral absorption, although these efforts have been largely separate; this work aimed to integrate knowledge from these approaches to investigate the oral absorption of a RET inhibitor, pralsetinib, with BCS Class II properties. Tiny-TIM (TIM B.V.
View Article and Find Full Text PDFArticle Synopsis
- In oncology drug development, traditional models that use specific tumor dynamics to predict patient survival have limitations, especially for tumor types with limited prior data.
- The authors suggest a new machine learning approach that analyzes multiple tumor metrics simultaneously, allowing for predictions of overall survival that aren't tied to specific tumor types.
- Their study showed this machine learning method effectively predicts survival in various solid tumors treated with pralsetinib, but more research is needed to confirm its applicability across different tumor types.
A study to determine the impact of cyclosporine (Neoral), an inhibitor of P-gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO®) was conducted in 15 healthy adult volunteers. A single 200 mg dose of pralsetinib was administered orally alone and in combination with cyclosporine with a 9-day washout between treatments. Co-administration with cyclosporine resulted in a clinically relevant increase in pralsetinib maximum plasma concentration (C) and area under the plasma concentration-time curve extrapolated to infinity (AUC) with associated geometric mean ratios (GMRs) and 90% confidence intervals (CIs) of 148% (109, 201) and 181% (136, 241), respectively.
View Article and Find Full Text PDFPralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection () fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely alter its pharmacokinetics (PK). Mild HI has been shown to have minimal impact on the PK of pralsetinib.
View Article and Find Full Text PDF